Practical implementation of oncolytic virus therapy in the hospital: safety protocols and operational guidelines
Abstract
The integration of oncolytic virus (OV) therapies into clinical practice introduces unique challenges for hospitals and healthcare teams. Unlike conventional cancer drugs, OVs are live replicating viruses, requiring special handling, storage, and safety precautions. This article reviews key operational considerations for safely implementing oncolytic virotherapy in a hospital setting. Topics include biosafety protocols (classification of OVs as BioSafety Level 2 agents, personal protective equipment, and staff training), cold-chain logistics (ultra-low temperature storage and thawing procedures), preparation and administration guidelines (compounding live virus doses in pharmacy cleanrooms and intratumoral injection techniques), and containment measures to prevent unintended exposure or viral shedding to healthcare workers and patients’ contacts. We discuss the development of standard operating procedures (SOPs) and the importance of interdisciplinary coordination among pharmacy, nursing, infection control, and clinical teams. Practical steps – from handling biohazardous waste to patient counseling on post-treatment precautions – are outlined. By establishing robust protocols and training programs, hospitals can safely deliver these novel therapies. This review provides a framework for institutions to navigate the logistical and safety aspects of oncolytic virotherapy, ensuring maximal benefit to patients while protecting staff and the public.
Keywords:
Oncolytic virotherapy, Hospital implementation, Biosafety, Cold chain, Viral shedding, Standard operating procedures, Pharmacy, Infection control, Intratumoral injectionDOI
https://doi.org/10.70604/References
1. Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, et al. A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). Oncoimmunology [Internet]. 2018 Jul 23 [cited 2025 Sep 7];7(9):e1478648. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140583/
2. Nguyen HM, Sah N, Humphrey MRM, Rabkin SD, Saha D. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus. J Vis Exp. 2021 May 13;(171).
3. Chen L, Zuo M, Zhou Q, Wang Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol [Internet]. 2023 Dec 15 [cited 2025 Sep 7];14. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1308890/full
4. Mestiri S, Sami A, Sah N, El-Ella DMA, Khatoon S, Shafique K, et al. Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapies. Cancer Metastasis Rev. 2025 Jan 25;44(1):27.
5. Acharya G, Mani C, Sah N, Saamarthy K, Young R, Reedy MB, et al. CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer. Cell Death Discov. 2024 Jun 11;10(1):278.
6. McBride A, Valgus J, Parsad S, Sommermann EM, Nunan R. Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec. Hosp Pharm [Internet]. 2018 Oct [cited 2025 Sep 7];53(5):296–302. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130110/
7. Wang H, Borlongan M, Hemminki A, Basnet S, Sah N, Kaufman HL, et al. Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy. Hum Gene Ther. 2023 Sep;34(17–18):878–95.
8. Robilotti E, Zeitouni NC, Orloff M. Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy. Front Mol Biosci [Internet]. 2023 Sep 12 [cited 2025 Sep 8];10:1178382. Available from: https://www.frontiersin.org/articles/10.3389/fmolb.2023.1178382/full
9. Connor TH. Hazardous Anticancer Drugs in Health Care: Environmental Exposure Assessment. Annals of the New York Academy of Sciences [Internet]. 2006 Sep [cited 2025 Sep 8];1076(1):615–23. Available from: https://nyaspubs.onlinelibrary.wiley.com/doi/10.1196/annals.1371.021
10. Robilotti E, Zeitouni NC, Orloff M. Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy. Front Mol Biosci [Internet]. 2023 Sep 12 [cited 2025 Sep 8];10:1178382. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546393/
11. Nitrile-Xtra P, Underguard P, Nitrile-Xtra S. BE IN COMPLIANCE WITH HALYARD* CHEMO GEAR.
12. Casanova L, Alfano-Sobsey E, Rutala WA, Weber DJ, Sobsey M. Virus Transfer from Personal Protective Equipment to Healthcare Employees’ Skin and Clothing. Emerg Infect Dis [Internet]. 2008 Aug [cited 2025 Sep 8];14(8):1291–3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600382/
13. Varghese J, Sah N, Ramaiah B. PDG50 Obstacles in the IV to ORAL Antibiotic Shift for Eligible Patients at a Tertiary Care Hospital. Value in Health [Internet]. 2020 Dec 1 [cited 2025 Sep 8];23:S527. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(20)32989-2/fulltext
14. CDC. Healthcare-Associated Infections (HAIs). 2024 [cited 2025 Sep 8]. Basic Infection Control and Prevention Plan for Outpatient Oncology Settings. Available from: https://www.cdc.gov/healthcare-associated-infections/hcp/prevention-healthcare/infection-control-outpatient-oncology.html
15. Huddleston C, Mani C, Sah N, Courtney E, Reese K, Stroever S, et al. Evaluating Efficacy of Cervical HPV-HR DNA Testing as Alternative to PET/CT Imaging for Posttreatment Cancer Surveillance: Retrospective Proof-of-Concept Study. Cancer Epidemiol Biomarkers Prev. 2025 Aug 1;34(8):1264–8.
16. Okechukwu CC, Ma X, Sah N, Mani C, Palle K, Gmeiner WH. Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model. Cancers (Basel). 2024 Mar 30;16(7):1360.
17. Schumacher TJ, Sah N, Palle K, Rumbley J, Mereddy VR. Synthesis and biological evaluation of benzofuran piperazine derivatives as potential anticancer agents. Bioorg Med Chem Lett. 2023 Sep 1;93:129425.
18. Robilotti EV, Kumar A, Glickman MS, Kamboj M. Viral oncolytic immunotherapy in the war on cancer: Infection control considerations. Infect Control Hosp Epidemiol [Internet]. 2019 Mar [cited 2025 Sep 8];40(3):350–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859840/
19. Sah N, Ramaiah B, Koneri R. Sulfasalazine-induced drug rash with eosinophilia and systemic symptoms syndrome in a seronegative spondyloarthritis patient: A Case report. Indian J Pharmacol. 2021;53(5):391–3.
20. Robilotti EV, Kumar A, Glickman MS, Kamboj M. Viral oncolytic immunotherapy in the war on cancer: Infection control considerations. Infect Control Hosp Epidemiol [Internet]. 2019 Mar [cited 2025 Sep 8];40(3):350–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859840/
21. Kiser ML. Spill of agent OUTSIDE of a Biosafety Cabinet (BSC).
22. Needle-stick Guideline Treatment & Management: Approach Considerations, Prehospital Care, Emergency Department Care. 2025 Mar 28 [cited 2025 Sep 8]; Available from: https://emedicine.medscape.com/article/784812-treatment
23. Pan L, Liu X, Fan D, Qian Z, Sun X, Wu P, et al. Study of Oncolytic Virus Preservation and Formulation. Pharmaceuticals (Basel) [Internet]. 2023 Jun 5 [cited 2025 Sep 8];16(6):843. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302305/
24. Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration [Internet]. [cited 2025 Sep 8]. Available from: https://www.pharmacytimes.org/courses/exploring-oncolytic-viruses-in-melanoma-pharmacist-led-approaches-for-safe-integration-8rew
25. Sah N, Ramaiah B, Koneri R. The Pharmacist Role in Clinical Audit at an Indian Accredited Hospital: An Interventional Study. IJOPP [Internet]. 2019 Jun 1 [cited 2025 Sep 8];12(2):117–25. Available from: http://ijopp.org/article/662
26. Disposing of Medical Waste Properly [Internet]. 2025 [cited 2025 Sep 8]. Available from: https://www.actenviro.com/medical-waste-disposal-guide/
27. Research C for DE and. FDA. FDA; 2023 [cited 2025 Sep 8]. Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel. Available from: https://www.fda.gov/medical-devices/consumer-products/safely-using-sharps-needles-and-syringes-home-work-and-travel
28. Sheth RA, Wehrenberg-Klee E, Patel SP, Brock KK, Fotiadis N, de Baère T. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions. Radiology [Internet]. 2024 Jul [cited 2025 Sep 8];312(1):e232654. Available from: https://pubs.rsna.org/doi/full/10.1148/radiol.232654
29. Huddleston C, Fakhreddine AB, Stroever S, Young R, Sah N, Palle K, et al. Abstract 1305: Comparison of HPV-DNA testing to PET-CT imaging as prognostic test following definitive treatment for cervical cancer: A retrospective proof-of-concept study. Cancer Res [Internet]. 2024 Mar 22 [cited 2025 Sep 8];84(6_Supplement):1305. Available from: https://doi.org/10.1158/1538-7445.AM2024-1305
30. Huddleston C, Mani C, Sah N, Courtney E, Reese K, Stroever S, et al. Evaluating Efficacy of Cervical HPV-HR DNA Testing as Alternative to PET/CT Imaging for Posttreatment Cancer Surveillance: Retrospective Proof-of-Concept Study. Cancer Epidemiol Biomarkers Prev [Internet]. 2025 Aug 1 [cited 2025 Sep 8];34(8):1264–8. Available from: https://doi.org/10.1158/1055-9965.EPI-24-1828
31. Guan X, Yan H, Zhang J, Li Y, Zhou Y. Risk factors of infection of totally implantable venous access port: A retrospective study. J Vasc Access [Internet]. 2023 Nov 1 [cited 2025 Sep 8];24(6):1340–8. Available from: https://doi.org/10.1177/11297298221085230
32. Oncolytic Virus Therapy: What It Is, How It Works & Risks [Internet]. 2024 [cited 2025 Sep 8]. Available from: https://www.cityofhope.org/tests-procedures-treatments/oncolytic-virus-therapy
33. Roestenberg M, Mo A, Kremsner PG, Yazdanbakhsh M. Controlled human infections: A report from the controlled human infection models workshop, Leiden University Medical Centre 4–6 May 2016. Vaccine [Internet]. 2017 Dec 18 [cited 2025 Sep 8];35(51):7070–6. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X17315219
34. Sah N, Shaik AA, Acharya G, Dunna M, Silwal A, Sharma S, et al. Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy. Receptors [Internet]. 2024 Dec [cited 2025 Sep 8];3(4):425–43. Available from: https://www.mdpi.com/2813-2564/3/4/21
35. Sah N, Luna P, Mani C, Gmeiner W, Palle K. A Novel Fluoropyrimidine Drug to Treat Recalcitrant Colorectal Cancer. The Journal of Pharmacology and Experimental Therapeutics [Internet]. 2023 Jun 1 [cited 2025 Sep 8];385:441. Available from: https://www.sciencedirect.com/science/article/pii/S0022356524168796
36. Spirito F, Nocini R, Mori G, Albanese M, Georgakopoulou EA, Sivaramakrishnan G, et al. The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review. Int J Mol Sci [Internet]. 2024 Dec 3 [cited 2025 Sep 8];25(23):12990. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11641702/
37. Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, et al. Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3–targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer [Internet]. 2025 [cited 2025 Sep 8];131(3):e35738. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35738
38. Mohammed HS, Mohammad ZAE lateef, Azer SZ, Khallaf SM. Impact of In- Service Training Program on Nurses’ Performance for Minimizing Chemotherapy Extravasation. Asian Pac J Cancer Prev [Internet]. 2023 [cited 2025 Sep 8];24(10):3537–42. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770676/
39. Harrington KJ, Michielin O, Malvehy J, Pezzani Grüter I, Grove L, Frauchiger AL, et al. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 2017;10:3867–80.
40. Richardson B, Anderson A, Lakey K, Hickham L, Sah N, Mani C, et al. Assessing the Need and Implementation of Health Literacy Testing for New Gynecologic Oncology Patients in West Texas: A Prospective Pilot Study. Texas Public Health Journal [Internet]. 2025 Jan 1 [cited 2025 Sep 8];77(1):18–24. Available from: https://research.ebsco.com/linkprocessor/plink?id=bd8e0ed4-6f24-37d8-b569-cdff4cff5da9
41. Mason TM. Personal protective equipment for antineoplastic safety. Nursing [Internet]. 2023 Aug [cited 2025 Sep 8];53(8):42–5. Available from: https://journals.lww.com/10.1097/01.NURSE.0000942856.87753.8a
42. Sah N, Ramaiah B, Abdulla, Gupta AK, Thomas SM. Noncompliance with Prescription-Writing Guidelines in an OutpatientDepartment of a Tertiary Care Hospital: A Prospective, Observational Study. rjps [Internet]. 2020 [cited 2025 Sep 8];10(1). Available from: https://rjps.journalgrid.com/view/article/rjps/284
43. Terrie YC, Pharm BS, RPh, Pharmacist C. The Impact of Patient Education in Oncology/Hematology Care: Empowering Patients in Their Battle Against Cancer. First Report Managed Care [Internet]. 2020 Aug 31 [cited 2025 Sep 8];17(7). Available from: https://www.hmpgloballearningnetwork.com/site/frmc/articles/impact-patient-education-oncologyhematology-care-empowering-patients-their-battle-against
44. Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, et al. A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). Oncoimmunology [Internet]. 2018 Jul 23 [cited 2025 Sep 8];7(9):e1478648. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140583/
45. Stewart P. Fostering Partnerships With Patients Is Essential for Ensuring High-Quality Cancer Care. 2023 Jul 26 [cited 2025 Sep 8]; Available from: https://theoncologynurse.com/articles/fostering-partnerships-with-patients-is-essential-for-ensuring-high-quality-cancer-care
46. Varghese J, Sah N, Thomas SM, Jose JC, Ramaiah B, Koneri R. PDG6 Clinical Evaluation of Skin and Soft Tissue Infections in Inpatient Versus Outpatient Setting at a Tertiary Care Hospital - a Prospective Study. Value in Health [Internet]. 2020 Dec 1 [cited 2025 Sep 8];23:S521–2. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(20)32945-4/fulltext
Published
Abstract Display: 5 
PDF Downloads: 1 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
.